Editorial: Blank-check stem cells - Governor missed chance with state loan
By Sacramento Bee,
Sacramento Bee
| 07. 24. 2006
Embryonic stem cell research would seem to be an all-or-nothing proposition. Either you oppose use of embryos for medical science, supporting President Bush in his callous veto of expanded federal funding for such research, or you rally behind unfettered expenditures for regenerative medicine, with little governmental oversight over how public monies are allocated.
Actually, there is a third wave of opinion on stem cells, but you won't hear it from many politicians in this election season. The third wave supports increased spending for embryonic stem cell science, but wants safeguards to ensure that researchers stay within clear ethical lines. It wants transparency in decision-making and accountability to prevent money from being channeled inappropriately to favored researchers and biotech companies.
Last week, Gov. Arnold Schwarzenegger missed an opportunity to ally himself with this third wave. A day after Bush cast his first veto to reject a stem cell bill, Schwarzenegger announced a $150 million bridge loan to California's beleaguered stem cell research institute. This agency has been prevented from dispensing $3 billion in state funds -- authorized by voters in 2004...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...